195 related articles for article (PubMed ID: 34850411)
21. A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital.
AlBahrani S; Al-Tawfiq JA; Alshaer AR; Shilash A; Alswefy K; Al-Zayer RS; Abouelela AM
J Epidemiol Glob Health; 2021 Jun; 11(2):233-237. PubMed ID: 33605118
[TBL] [Abstract][Full Text] [Related]
22. Tocilizumab in the treatment of COVID-19-a meta-analysis.
Avni T; Leibovici L; Cohen I; Atamna A; Guz D; Paul M; Gafter-Gvili A; Yahav D
QJM; 2021 Nov; 114(8):577-586. PubMed ID: 34010403
[TBL] [Abstract][Full Text] [Related]
23. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients.
Duarte-Millán MA; Mesa-Plaza N; Guerrero-Santillán M; Morales-Ortega A; Bernal-Bello D; Farfán-Sedano AI; García de Viedma-García V; Velázquez-Ríos L; Frutos-Pérez B; De Ancos-Aracil CL; Soria Fernández-Llamazares G; Toledano-Macías M; Cristóbal-Bilbao R; Luquín-Ciuro N; Marrero-Francés J; Piedrabuena-García SI; Satué-Bartolomé JA; Gonzalo-Pascua S; Rivilla-Jiménez M; Carpintero-García L; Ayala-Larrañaga I; García-Bermúdez V; Lara-Montes C; Llerena-Riofrío ÁR; RIvas-Prado L; Walter S; Escriba-Barcena A; San Martín López JV; Ruíz-Giardín JM
J Med Virol; 2022 Apr; 94(4):1540-1549. PubMed ID: 34845754
[TBL] [Abstract][Full Text] [Related]
25. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
[TBL] [Abstract][Full Text] [Related]
26. Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies.
Malgie J; Schoones JW; Pijls BG
Clin Infect Dis; 2021 Jun; 72(11):e742-e749. PubMed ID: 32964913
[TBL] [Abstract][Full Text] [Related]
27. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.
Rezaei Tolzali MM; Noori M; Shokri P; Rahmani S; Khanzadeh S; Nejadghaderi SA; Fazlollahi A; Sullman MJM; Singh K; Kolahi AA; Arshi S; Safiri S
Rev Med Virol; 2022 Nov; 32(6):e2388. PubMed ID: 36029180
[TBL] [Abstract][Full Text] [Related]
29. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
Khan FA; Stewart I; Fabbri L; Moss S; Robinson K; Smyth AR; Jenkins G
Thorax; 2021 Sep; 76(9):907-919. PubMed ID: 33579777
[TBL] [Abstract][Full Text] [Related]
30. Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis.
Lim PC; Wong KL; Rajah R; Chong MF; Chow TS; Subramaniam S; Lee CY
Daru; 2022 Jun; 30(1):211-228. PubMed ID: 35084705
[TBL] [Abstract][Full Text] [Related]
31. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B
J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232
[TBL] [Abstract][Full Text] [Related]
32. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.
Martínez-Sanz J; Muriel A; Ron R; Herrera S; Pérez-Molina JA; Moreno S; Serrano-Villar S
Clin Microbiol Infect; 2021 Feb; 27(2):238-243. PubMed ID: 32979572
[TBL] [Abstract][Full Text] [Related]
33. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.
Selvaraj V; Khan MS; Bavishi C; Dapaah-Afriyie K; Finn A; Lal A; Mylonakis E
Lung; 2021 Jun; 199(3):239-248. PubMed ID: 34050796
[TBL] [Abstract][Full Text] [Related]
34. Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis.
Alkofide H; Almohaizeie A; Almuhaini S; Alotaibi B; Alkharfy KM
Int J Infect Dis; 2021 Sep; 110():320-329. PubMed ID: 34273515
[TBL] [Abstract][Full Text] [Related]
35. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.
Peng J; She X; Mei H; Zheng H; Fu M; Liang G; Wang Q; Liu W
Aging (Albany NY); 2022 Jan; 14(2):557-571. PubMed ID: 35038318
[TBL] [Abstract][Full Text] [Related]
36. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R
Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792
[TBL] [Abstract][Full Text] [Related]
37. Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients.
Marocco R; Carraro A; Zingaropoli MA; Nijhawan P; Tortellini E; Guardiani M; Mengoni F; Zuccalà P; Belvisi V; Kertusha B; Parente A; Del Borgo C; Vullo V; Ciardi MR; Mastroianni CM; Lichtner M
Front Immunol; 2022; 13():871592. PubMed ID: 35444637
[TBL] [Abstract][Full Text] [Related]
38. Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.
Martínez-Guerra BA; de-León-Cividanes NA; Tamez-Torres KM; Román-Montes CM; Rajme-López S; Ortiz-Brizuela E; Aguilar-Salinas CA; Sierra-Madero J; Sifuentes-Osornio J; Ponce-de-León A; González-Lara MF
Rev Invest Clin; 2022 Jan; 74(1):40-50. PubMed ID: 34618802
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.
Rezaei S; Fatemi B; Karimi Majd Z; Minaei H; Peikanpour M; Anjidani N; Taheri A; Dastan F; Mosaed R
Expert Rev Clin Immunol; 2021 May; 17(5):499-511. PubMed ID: 33823733
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
